PT - JOURNAL ARTICLE AU - Hasani, Hamidreza AU - Mardi, Shayan AU - Shakerian, Sareh AU - Taherzadeh-Ghahfarokhi, Nooshin AU - Mardi, Parham TI - The Novel Coronavirus Disease (COVID-19): A PRISMA Systematic Review and Meta-analysis of Clinical and Paraclinical characteristics AID - 10.1101/2020.04.19.20071456 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.19.20071456 4099 - http://medrxiv.org/content/early/2020/04/22/2020.04.19.20071456.short 4100 - http://medrxiv.org/content/early/2020/04/22/2020.04.19.20071456.full AB - An outbreak of pneumonia, caused by a novel coronavirus (COVID-19) was Identified in China in Dec 2019. This virus expanded worldwide, causing global concern. Clinical, laboratory and imaging features of this infection are characterized in some observational studies. We undertook a systematic review and meta-analysis to assess the frequency of clinical, laboratory, and CT features in COVID-19 patients.We did a systematic review and meta-analysis using three databases to identify clinical, laboratory, and CT features of rRT-PCR confirmed cases of COVID-19. Data for 3420 patients from 30 observational studies were included.Overall, the results showed that fever (84.2%, 95%CI 82.6-85.7), cough (62%, 95%CI 60-64), and fatigue (39.4%, 95%CI 37.2-41.6%) were the most prevalent symptoms in COVID-19 patients. Increased CRP level, decreased lymphocyte count, and increased D-dimer level were the most common laboratory findings. Among COVID-19 patients, 92% had a positive CT finding, most prevalently GGO (60%, 95%CI 58-62) and peripheral distribution (64%, 95%CI 60-69).These results demonstrate the clinical, paraclinical, and imaging features of COIVD-19.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno funding supported this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes-COVID-19Corona Virus Disease of 2019rRT-PCRreal-time Reverse Transcription–Polymerase Chain ReactionCT-scanComputed Tomography scanCIConfidence IntervalsCRPC-Reactive ProteinRNARibonucleic AcidSARS-CoV-2Severe Acute Respiratory Syndrome Corona Virus #2PRISMAprotocol based on transparent reporting of systematic reviews and meta-analysisCBCComplete Blood CountCMAcomprehensive meta-analysisGGOground-glass opacitiesβ-CoVbeta coronavirusMERSMiddle Eastern Respiratory SyndromeSARSSevere Acute Respiratory SyndromeLDHLactate DehydrogenaseWBCWhite Blood CellALTAlanine TransaminaseASTAspartate AminotransferaseINRInternational Normalized Ratio.